#United States #Redwood City #Lung Cancer #Aliya PEF #Galvanize

New Study on Aliya® PEF for Lung Cancer

A groundbreaking study published in the Journal of Surgical Oncology highlights the innovative use of Aliya® PEF (Pulsed Electric Field) technology in treating early-stage non-small cell lung cancer (NSCLC). Conducted by Galvanize Therapeutics, this multi-center study reveals promising results regarding the safety and feasibility of this novel approach prior to surgical tumor resection.

Overview of the Study

The study, titled INCITE-ES, involved 47 patients diagnosed with stage IA2-IB NSCLC. It employed a non-randomized, two-arm treatment design where patients underwent endoscopic or percutaneous delivery of Aliya PEF energy during a biopsy procedure. Remarkably, out of the 36 patients treated with Aliya PEF, no serious procedure-related adverse events were reported, showcasing the method's high safety profile.

Researchers noted the unique mechanism of Aliya PEF technology: it utilizes short bursts of high-voltage electrical pulses to effectively induce cell death in targeted cancer cells while sparing surrounding vital structures such as airways and blood vessels. Consequently, this method presents a less invasive treatment alternative compared to traditional thermal ablation techniques, emphasizing its advantages in preserving bodily functions without compromising patient safety.

Key Findings

1. Technical Success Rate of 100%

According to Dr. Marcelo Jimenez, the leading investigator and thoracic surgery professor at Salamanca University Hospital in Spain, the Aliya PEF ablation achieved a technical success rate of 100%. This significant finding highlights the technology's potential for seamless integration into existing clinical workflows. The procedure not only facilitated tumor ablation but also allowed for biopsy, minimizing the need for multiple anesthetic events.

2. Preservation of Lung Structures

The study also provided critical insights into the preservation of sensitive lung structures during treatment. Pathological evaluations revealed that delicate tissues surrounding tumors, even those adjacent to pleural surfaces or fissures, remained intact, reinforcing the anatomical safety of Aliya PEF ablation.

3. Immune Activation Indicators

An important observation was the detection of tertiary lymphoid structures (TLS) within and around treated tissues, suggesting possible immune activation following the application of Aliya PEF. This discovery raises exciting prospects regarding the potential for inducing immune responses against lung cancer post-treatment.

Compatibility with Surgical Resection

Another major takeaway from the study is the lack of any impact on planned surgical resections. The compatibility of Aliya PEF technology with standard care protocols further strengthens its clinical utility. Patients in the study exhibited no delays or complications in their surgical timelines, pointing towards the method's effective integration into cancer care.

Conclusion and Future Directions

The INCITE-ES study marks a promising advancement in the field of oncological treatments, particularly for lung cancer patients presenting challenges with conventional therapies. The findings put forth a strong case for the wider adoption of Aliya PEF technology, especially for tumors located near sensitive structures where other techniques may pose a higher risk.

As research continues, clinical trials exploring the application of Aliya PEF in larger cohorts, as well as its use in late-stage NSCLC and lung metastases, are already underway. The researchers at Galvanize are optimistic about the implications of these trials and their potential to change the landscape of lung cancer treatment.

For additional details about the findings of this study and other publications regarding Aliya PEF technology, please visit Galvanize Therapeutics.